Micafungin Sodium
FDA-approved product (injectable, intravenous), marketed as Micafungin, Micafungin In Sodium Chloride 0.9%, Micafungin Sodium and 1 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Candidiasis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other antimycotics for systemic use
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J02AX05
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA66.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli52.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae52.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis53.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Micafungin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- FurazolidoneExisting use: Other antiinfectives and antiseptics91.4% AI-predicted activityagainst M. tuberculosisLab records exist49 registered studies
- TriflupromazineExisting use: Psychosis90.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- ValdecoxibExisting use: Dysmenorrhea, Osteoarthritis, Rheumatic disease and 1 more88.6% AI-predicted activityagainst M. tuberculosisLab records exist31 registered studies
- CelecoxibExisting use: Ankylosing spondylitis, Cancer, Colorectal neoplasm and 15 more87.6% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Dorzolamide HydrochlorideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma86.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- MethazolamideExisting use: Glaucoma, Open-angle glaucoma85.6% AI-predicted activityagainst M. tuberculosisLab records exist11 registered studies
- AcetazolamideExisting use: Altitude sickness, Angle-closure glaucoma, Congestive heart failure and 5 more85.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Trifluoperazine HydrochlorideExisting use: Anxiety disorder, Mental or behavioural disorder, Psychosis and 1 more84.6% AI-predicted activityagainst M. tuberculosis1 registered study
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives84.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- NitrofurazoneExisting use: Eye infection, Leishmaniasis, Trypanosomiasis84.0% AI-predicted activityagainst M. tuberculosis8 registered studies
- BrinzolamideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma83.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- ZonisamideExisting use: Epilepsy, Focal-onset seizure, Partial epilepsy and 1 more82.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia
NCT00106288 · start 2003-01
Registered record
- Registry ID
- NCT00106288
- Conditions
- Candidiasis
- Interventions
- Micafungin; Liposomal Amphotericin B
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2003-01
- Completion
- 2005-12
- Enrolment
- 637
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCandidiasisInterventionMicafungin; Liposomal Amphotericin BPhasePhase 3Registry statusCompletedTrial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis
NCT00047827 · start 2002-12
Registered record
- Registry ID
- NCT00047827
- Conditions
- Aspergillosis
- Interventions
- Micafungin; Liposomal Amphotericin B
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2002-12
- Completion
- 2003-02
- Enrolment
- 2
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAspergillosisInterventionMicafungin; Liposomal Amphotericin BPhasePhase 2Registry statusTerminatedStudy of FK463 in the Treatment of Candidemia or Invasive Candidiasis
NCT00036179 · start 1999-02-27
Registered record
- Registry ID
- NCT00036179
- Conditions
- Candidiasis
- Interventions
- FK463
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 1999-02-27
- Completion
- 2002-01-27
- Enrolment
- 75
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCandidiasisInterventionFK463PhasePhase 2Registry statusCompletedStudy of FK463 for the Treatment of Invasive Aspergillosis
NCT00036166 · start 1999-01-29
Registered record
- Registry ID
- NCT00036166
- Conditions
- Aspergillosis
- Interventions
- FK463
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 1999-01-29
- Completion
- 2002-01-31
- Enrolment
- 326
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAspergillosisInterventionFK463PhasePhase 2Registry statusCompletedPhase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia
NCT00001790 · start 1998-10
Registered record
- Registry ID
- NCT00001790
- Conditions
- Fever; Mycoses; Neutropenia
- Interventions
- FK463
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 1998-10
- Completion
- 2000-09
- Enrolment
- 120
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionFever; Mycoses; NeutropeniaInterventionFK463PhasePhase 1Registry statusCompleted